DZ2891A1 - Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. - Google Patents

Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Info

Publication number: DZ2891A1
Authority: DZ; Algeria
Prior art keywords: preparation; pharmaceutical compositions; compositions containing; new substituted; tetrahydroquinoline derivatives
Prior art date: 1998-09-17

Application number

DZ990191A

Other languages

English (en)

Inventor

Michael Paul Deninno

George Tetteh

Magnus Aryitey

Roger Benjamin Ruggeri

Ronald Thure Wester

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

1999-09-13

Publication date

2003-12-15

1999-09-13 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2891A1 publication Critical patent/DZ2891A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DZ990191A 1998-09-17 1999-09-13 Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. DZ2891A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10092798P	1998-09-17	1998-09-17

Publications (1)

Publication Number	Publication Date
DZ2891A1 true DZ2891A1 (fr)	2003-12-15

Family

ID=22282246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990191A DZ2891A1 (fr)	1998-09-17	1999-09-13	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.

Country Status (50)

Country	Link
US (2)	US6140343A (fr)
EP (1)	EP1114032B1 (fr)
JP (1)	JP3561474B2 (fr)
KR (1)	KR100422286B1 (fr)
CN (2)	CN1515259A (fr)
AP (1)	AP1345A (fr)
AR (1)	AR030523A1 (fr)
AT (1)	ATE268324T1 (fr)
AU (1)	AU747715B2 (fr)
BG (1)	BG65101B1 (fr)
BR (1)	BR9913855A (fr)
CA (1)	CA2344248C (fr)
CO (1)	CO5290250A1 (fr)
CR (1)	CR6306A (fr)
CU (1)	CU23053A3 (fr)
CZ (1)	CZ2001954A3 (fr)
DE (1)	DE69917790T2 (fr)
DK (1)	DK1114032T3 (fr)
DZ (1)	DZ2891A1 (fr)
EA (1)	EA005761B1 (fr)
EE (1)	EE200100167A (fr)
ES (1)	ES2221420T3 (fr)
GC (1)	GC0000108A (fr)
GE (1)	GEP20032973B (fr)
GT (1)	GT199900147A (fr)
HK (1)	HK1039938A1 (fr)
HR (1)	HRP20010200B1 (fr)
HU (1)	HUP0103512A3 (fr)
ID (1)	ID27838A (fr)
IL (1)	IL141388A0 (fr)
IS (1)	IS2278B (fr)
MA (1)	MA26689A1 (fr)
MY (1)	MY121405A (fr)
NO (1)	NO319781B1 (fr)
NZ (1)	NZ509837A (fr)
OA (1)	OA11651A (fr)
PA (1)	PA8481201A1 (fr)
PE (1)	PE20001054A1 (fr)
PL (1)	PL198124B1 (fr)
PT (1)	PT1114032E (fr)
SI (1)	SI1114032T1 (fr)
SK (1)	SK3532001A3 (fr)
SV (1)	SV1999000150A (fr)
TN (1)	TNSN99170A1 (fr)
TR (1)	TR200100780T2 (fr)
TW (1)	TW502022B (fr)
UA (1)	UA70960C2 (fr)
WO (1)	WO2000017165A1 (fr)
YU (1)	YU18101A (fr)
ZA (1)	ZA200101745B (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US7115279B2 (en)	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv)	2001-03-30	2001-03-30	Astrazeneca Ab	New compounds
AU2002320025A1 (en) *	2001-04-11	2002-11-11	Atherogenics, Inc.	Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
ATE321755T1 (de)	2001-04-30	2006-04-15	Pfizer Prod Inc	Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
JP2005500314A (ja) *	2001-06-21	2005-01-06	ファイザー・プロダクツ・インク	コレステロールエステル転送蛋白インヒビターの自己乳化性製剤
EP1269994A3 (fr)	2001-06-22	2003-02-12	Pfizer Products Inc.	Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
ATE486586T1 (de)	2001-06-22	2010-11-15	Pfizer Prod Inc	Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
PT1404300E (pt) *	2001-06-22	2009-11-09	Bend Res Inc	Composições farmacêuticas de dispersões de fármacos e polímeros neutros
CA2470931A1 (fr) *	2001-12-19	2003-07-03	Atherogenics, Inc.	Derives de chalcone et leur utilisation dans le traitement de maladies
US7202247B2 (en)	2001-12-19	2007-04-10	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1458382A1 (fr) *	2001-12-21	2004-09-22	Novo Nordisk A/S	Derives amide utiles en tant qu'activateurs de la glucokinase
ES2878403T3 (es) *	2002-02-01	2021-11-18	Bend Res Inc	Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60320940D1 (de) *	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
WO2003063868A1 (fr) *	2002-02-01	2003-08-07	Pfizer Products Inc.	Forme posologique a liberation controlee d'une proteine inhibant le transfert du cholesteryl ester
JP4881559B2 (ja) *	2002-06-27	2012-02-22	ノボ・ノルデイスク・エー／エス	治療薬としてのアリールカルボニル誘導体
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556047A4 (fr) *	2002-10-04	2009-09-30	Millennium Pharm Inc	Antagonistes vis-a-vis du recepteur pgd2 pour le traitement de maladies inflammatoires
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
DE60305724T2 (de) *	2002-10-21	2006-11-09	Warner-Lambert Co. Llc	Tetrahydrochinolin-derivate als crth2 antagonisten
JPWO2004052863A1 (ja) *	2002-12-06	2006-04-13	協和醗酵工業株式会社	抗炎症剤
AU2003303239A1 (en) *	2002-12-19	2004-07-14	Atherogenics, Inc.	Process of making chalcone derivatives
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de)	2002-12-20	2008-09-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1435356A1 (fr) *	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Dérivés de la quinoléine en tant qu'antagonistes de CRTH2
WO2004072042A2 (fr) *	2003-02-12	2004-08-26	Carex S.A.	Modulation de l'activite de recepteurs nucleaires
KR20050110017A (ko) *	2003-03-17	2005-11-22	니뽄 다바코 산교 가부시키가이샤	Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
MXPA05009848A (es) *	2003-03-17	2005-12-06	Japan Tobacco Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
JP2006521344A (ja) *	2003-03-28	2006-09-21	ファイザー・プロダクツ・インク	アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2526730A1 (fr)	2003-05-30	2004-12-09	Ranbaxy Laboratories Limited	Derives pyrroliques substitues
WO2005011635A2 (fr)	2003-08-04	2005-02-10	Pfizer Products Inc.	Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005030185A2 (fr)	2003-09-26	2005-04-07	Japan Tobacco Inc.	Procede pour inhiber la production de lipoproteines restantes
JP2007507481A (ja) *	2003-09-30	2007-03-29	ファイザー・プロダクツ・インク	Ｃｅｔｐ阻害薬及びその代謝産物
MXPA06003927A (es)	2003-10-08	2008-02-07	Lilly Co Eli	Compuestos y metodos para tratar dislipidemia.
CA2543596A1 (fr) *	2003-11-07	2005-05-26	Jj Pharma, Inc.	Complexes pour une therapie combinatoire stimulant les hdl
RU2386622C9 (ru) *	2004-01-06	2021-04-21	Ново Нордиск А/С	Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
JP5697296B2 (ja)	2004-03-05	2015-04-08	ザトラスティーズオブザユニバーシティオブペンシルバニア	高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
ES2326326T3 (es)	2004-03-26	2009-10-07	Eli Lilly And Company	Compuestos y procedimientos para tratar la dislipidemia.
UA90269C2 (ru) *	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
MY139887A (en) *	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20050282812A1 (en) *	2004-06-18	2005-12-22	JONES Zachary	Inhibitors of cholesteryl ester transfer protein
EP1761521A1 (fr) *	2004-06-24	2007-03-14	Eli Lilly And Company	Composés et procédés destinés à traiter la dyslipidémie
KR100859223B1 (ko) *	2004-06-24	2008-09-18	일라이 릴리 앤드 캄파니	이상지혈증 치료를 위한 화합물 및 방법
US20060063828A1 (en) *	2004-06-28	2006-03-23	Weingarten M D	1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es)	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
DE602005020462D1 (de)	2004-08-25	2010-05-20	Essentialis Inc	Pharmazeutische formulierungen von kalium-atp-kanalöffnern und deren verwendungen
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2006033004A1 (fr) *	2004-09-23	2006-03-30	Pfizer Products Inc.	Composes de quinoline en tant qu'inhibiteurs de cetp
ES2328384T3 (es) *	2004-11-23	2009-11-12	Warner-Lambert Company Llc	Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US7700774B2 (en) *	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
CN103102303B (zh)	2004-12-31	2015-10-28	雷迪博士实验室有限公司	作为cetp抑制剂的苄胺衍生物
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2548894A1 (fr)	2005-02-03	2013-01-23	Bend Research, Inc.	Compositions pharmaceutiques à éfficacité améliorée
CN101146776A (zh)	2005-02-24	2008-03-19	米伦纽姆医药公司	治疗炎性疾病的pgd2受体拮抗剂
WO2006098394A1 (fr) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
EP2985022B1 (fr) *	2005-07-01	2018-09-12	Merck Sharp & Dohme Corp.	Procédé de synthèse d'un inhibiteur de cetp
EP1904438B1 (fr) *	2005-07-08	2012-02-29	Novo Nordisk A/S	Dicycloalkylcarbamoylurées en tant qu' activateurs de glucokinase
CA2614518A1 (fr) *	2005-07-08	2007-01-18	Novo-Nordisk A/S	Activateurs de dicycloalkyluree glucokinase
EP1904467B1 (fr) *	2005-07-14	2013-05-01	Novo Nordisk A/S	Activateurs de l'urée glucokinase
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
JP4531027B2 (ja) *	2005-09-29	2010-08-25	田辺三菱製薬株式会社	医薬組成物
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
BRPI0618379A2 (pt)	2005-11-08	2011-08-30	Ranbaxy Lab Ltd	processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
HRP20120005T1 (hr)	2006-01-05	2012-01-31	Essentialis	Soli otvarača kalijskih kanala i njihova upotreba
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
PE20071025A1 (es)	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
UY30244A1 (es)	2006-03-30	2007-11-30	Tanabe Seiyaku Co	Un proceso para preparar derivados de tetrahidroquinolina
GB0615670D0 (en) *	2006-08-07	2006-09-13	Syngenta Participations Ag	Chemical compounds
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
TW200831497A (en) *	2006-10-12	2008-08-01	Epix Delaware Inc	Carboxamide compounds and their use
ES2382009T3 (es)	2006-12-01	2012-06-04	Bristol-Myers Squibb Company	Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
AU2007338625A1 (en) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Methods for treating obesity with a combination comprising a MTP inhibitor and a cholesterol absorption inhibitor
JP2010515701A (ja) *	2007-01-09	2010-05-13	ノボ・ノルデイスク・エー／エス	ウレアグルコキナーゼアクチベーター
EP2099777B1 (fr)	2007-01-11	2015-08-12	Novo Nordisk A/S	Activateurs de l'urée glucokinase
CN101220021B (zh) *	2007-01-12	2010-12-08	上海医药工业研究院	4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
AU2008241904B2 (en)	2007-04-13	2012-06-07	Kowa Company, Ltd.	Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
WO2009006483A1 (fr) *	2007-07-02	2009-01-08	Essentialis, Inc.	Sels d'ouvreurs de canaux potassiques sensibles à l'atp et leurs utilisations
ES2381518T3 (es)	2007-11-05	2012-05-29	Novartis Ag	Derivados del 4-bencilamino-1-carboxi acil-piperidina como inhibidores de CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteroesclerosis
CN101878199B (zh)	2007-12-03	2013-09-18	诺瓦提斯公司	用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
BRPI0820701A2 (pt)	2007-12-11	2015-06-16	Cytopathfinder Inc	Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
SG175925A1 (en)	2009-05-15	2011-12-29	Novartis Ag	Aryl pyridine as aldosterone synthase inhibitors
EA201101621A1 (ru)	2009-05-15	2012-05-30	Новартис Аг	Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
SI2435409T1 (sl)	2009-05-28	2014-12-31	Novartis Ag	Substituirani aminopropionski derivati kot inhibitorji neprilizina
EA201101672A1 (ru)	2009-05-28	2012-06-29	Новартис Аг	Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AR077208A1 (es)	2009-06-30	2011-08-10	Lilly Co Eli	Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
WO2011061168A1 (fr)	2009-11-17	2011-05-26	Novartis Ag	Dérivés d'aryl-pyridine en tant qu'inhibiteurs d'aldostérone synthase
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en)	2009-11-30	2013-11-05	Novartis Ag	Imidazole derivatives as aldosterone synthase inhibitors
US20130072519A1 (en)	2010-05-21	2013-03-21	Edward Lee Conn	2-phenyl benzoylamides
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012101142A1 (fr)	2011-01-26	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
JP2014513923A (ja)	2011-03-04	2014-06-19	ファイザー・インク	Ｅｄｎ３様ペプチドおよびその使用
KR101599157B1 (ko)	2011-06-17	2016-03-02	머크 샤프 앤드 돔 코포레이션	Crth₂ 수용체 조절제로서의 시클로알킬-융합된 테트라히드로퀴놀린
AR087451A1 (es) *	2011-08-17	2014-03-26	Lilly Co Eli	Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
KR101774223B1 (ko)	2011-08-18	2017-09-12	닥터 레디스 레보러터리즈 리미티드	콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
AU2012313971B2 (en)	2011-09-27	2016-09-29	Dr. Reddy's Laboratories, Ltd.	5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
MX347400B (es)	2012-06-29	2017-04-18	Univ Nac Autónoma De México	Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja)	2013-02-14	2018-03-14	ノバルティスアーゲー	Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
BR112015026513A2 (pt)	2013-04-17	2017-07-25	Pfizer	derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
AU2014293386B2 (en)	2013-07-25	2016-11-17	Novartis Ag	Cyclic polypeptides for the treatment of heart failure
JP2016527249A (ja)	2013-07-25	2016-09-08	ノバルティスアーゲー	合成アペリンポリペプチドのバイオコンジュゲート
CN107072999A (zh) *	2014-08-28	2017-08-18	狄智玛制药私人有限公司	包含胆固醇酯转运蛋白抑制剂和HMG CoA还原酶抑制剂的药物组合物和治疗组合
MX389591B (es)	2014-08-29	2025-03-20	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
BR112017014194A2 (pt)	2015-01-23	2018-01-09	Novartis Ag	conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
JP2021526130A (ja)	2018-06-12	2021-09-30	ブイティーブイ・セラピューティクス・エルエルシー	インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
FI3911648T3 (fi)	2019-01-18	2025-01-10	Astrazeneca Ab	6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
US12391658B2 (en)	2020-02-18	2025-08-19	Vtv Therapeutics Llc	Sulfoxide and sulfone glucokinase activators and methods of use thereof
KR20230048502A (ko)	2020-06-08	2023-04-11	브이티브이 테라퓨틱스 엘엘씨	｛2-[3-사이클로헥실-3-(트랜스-4-프로폭시-사이클로헥실)-우레이도]-티아졸-5-일설파닐｝-아세트산의 염 또는 공결정 및 그의 용도
CN116322682A (zh)	2020-07-29	2023-06-23	艾米琳制药有限责任公司	在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
CN121219288A (zh)	2023-05-24	2025-12-26	诺华股份有限公司	用于治疗疾病或障碍的萘啶酮衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231102A (en) *	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en)	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
JPH0676403B2 (ja) *	1991-01-18	1994-09-28	エスエス製薬株式会社	新規なベンゾ［５，６シクロヘプタ［１，２−ｂピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) *	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) *	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000038722A1 (fr)	1998-12-23	2000-07-06	G.D. Searle & Co.	COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES

1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 CA CA002344248A patent/CA2344248C/fr not_active Expired - Fee Related
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 EE EEP200100167A patent/EE200100167A/xx unknown
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/fr not_active Ceased
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 EP EP99940426A patent/EP1114032B1/fr not_active Expired - Lifetime
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 HK HK02101447.5A patent/HK1039938A1/zh unknown
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active Expired - Fee Related
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/fr active
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown

Also Published As

Publication number	Publication date
SV1999000150A (es)	2000-06-06
DE69917790T2 (de)	2005-06-09
HK1039938A1 (zh)	2002-05-17
EA005761B1 (ru)	2005-06-30
ATE268324T1 (de)	2004-06-15
AR030523A1 (es)	2003-08-27
NO319781B1 (no)	2005-09-12
MA26689A1 (fr)	2004-12-20
CZ2001954A3 (cs)	2001-12-12
ES2221420T3 (es)	2004-12-16
JP3561474B2 (ja)	2004-09-02
NO20011349D0 (no)	2001-03-16
AU5440399A (en)	2000-04-10
CU23053A3 (es)	2005-06-24
HRP20010200A2 (en)	2002-04-30
JP2002526476A (ja)	2002-08-20
SI1114032T1 (fr)	2004-12-31
NO20011349L (no)	2001-05-14
KR100422286B1 (ko)	2004-03-11
NZ509837A (en)	2002-11-26
US6489478B1 (en)	2002-12-03
EA200100249A1 (ru)	2001-08-27
CR6306A (es)	2003-08-28
IS2278B (is)	2007-09-15
YU18101A (sh)	2004-05-12
UA70960C2 (uk)	2004-11-15
PL346830A1 (en)	2002-02-25
TW502022B (en)	2002-09-11
DE69917790D1 (de)	2004-07-08
MY121405A (en)	2006-01-28
EE200100167A (et)	2002-06-17
CA2344248C (fr)	2007-01-09
US6140343A (en)	2000-10-31
WO2000017165A1 (fr)	2000-03-30
EP1114032A1 (fr)	2001-07-11
HUP0103512A3 (en)	2002-03-28
GC0000108A (en)	2005-06-29
IS5858A (is)	2001-02-23
ZA200101745B (en)	2002-05-02
DK1114032T3 (da)	2004-08-16
HUP0103512A2 (hu)	2002-02-28
AU747715B2 (en)	2002-05-23
CA2344248A1 (fr)	2000-03-30
AP1345A (en)	2004-12-15
BG105429A (en)	2001-12-29
EP1114032B1 (fr)	2004-06-02
IL141388A0 (en)	2002-03-10
PL198124B1 (pl)	2008-05-30
ID27838A (id)	2001-04-26
GEP20032973B (en)	2003-05-27
CN1515259A (zh)	2004-07-28
BR9913855A (pt)	2001-07-24
PT1114032E (pt)	2004-09-30
KR20010085814A (ko)	2001-09-07
OA11651A (en)	2004-12-07
SK3532001A3 (en)	2001-12-03
TNSN99170A1 (fr)	2005-11-10
CO5290250A1 (es)	2003-06-27
GT199900147A (es)	1999-09-06
PA8481201A1 (es)	2000-09-29
PE20001054A1 (es)	2000-10-14
BG65101B1 (bg)	2007-02-28
TR200100780T2 (tr)	2001-07-23
AP2001002100A0 (en)	2001-03-31
CN1318057A (zh)	2001-10-17
HRP20010200B1 (en)	2006-10-31

Publication	Publication Date	Title
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2962A1 (fr)	2004-03-15	Dérivés de 3-azabicycloÄ3,1,0Ühexane nouveaux, procédé pour leur préparation et compositions les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2889A1 (fr)	2003-12-15	4-Carboxyamino-2-méthyl-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositionspharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2227A1 (fr)	2002-12-25	Dérivés d'indole nouveaux, procédé pour leur préparation et formulations pharmaceutiques les contenant.
DZ2880A1 (fr)	2003-12-15	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2457A1 (fr)	2004-11-08	Derivés de nicotinamide nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
MA26686A1 (fr)	2004-12-20	Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr)	2004-12-20	Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.